Differential survival following trastuzumab treatment based on quantitative HER2 expression and HER2 homodimers in a clinic-based cohort of patients with metastatic breast cancer
Open Access
- 23 February 2010
- journal article
- Published by Springer Nature in BMC Cancer
- Vol. 10 (1) , 56
- https://doi.org/10.1186/1471-2407-10-56
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Quantitation of HER2 Expression or HER2:HER2 Dimers and Differential Survival in a Cohort of Metastatic Breast Cancer Patients Carefully Selected for Trastuzumab Treatment Primarily by FISHDiagnostic Molecular Pathology, 2009
- A Novel Proximity Assay for the Detection of Proteins and Protein Complexes: Quantitation of HER1 and HER2 Total Protein Expression and Homodimerization in Formalin-fixed, Paraffin-Embedded Cell Lines and Breast Cancer TissueDiagnostic Molecular Pathology, 2009
- Adjuvant Trastuzumab: A Milestone in the Treatment of HER-2-Positive Early Breast CancerThe Oncologist, 2006
- p95HER-2 Predicts Worse Outcome in Patients with HER-2-Positive Breast CancerClinical Cancer Research, 2006
- Insulin-like Growth Factor-I Receptor/Human Epidermal Growth Factor Receptor 2 Heterodimerization Contributes to Trastuzumab Resistance of Breast Cancer CellsCancer Research, 2005
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- Relationship of Epidermal Growth Factor Receptor Expression to ErbB-2 Signaling Activity and Prognosis in Breast Cancer PatientsJournal of Clinical Oncology, 2005
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987